For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 182,147 | |||
| General and administrative | 703,444 | |||
| Depreciation | 1,159 | |||
| Total operating expenses | 886,750 | |||
| Loss from operations | -886,750 | |||
| Interest income | 1,078 | |||
| Interest expense | 38,219 | |||
| Other income | 600 | |||
| Total other income (expense), net | -36,541 | |||
| Net loss | -923,291 | |||
| Basic EPS | -0.2 | |||
| Diluted EPS | -0.2 | |||
| Basic Average Shares | 6,995,469 | |||
| Diluted Average Shares | 6,995,469 | |||
Lakewood-Amedex Biotherapeutics Inc. (LABT)
Lakewood-Amedex Biotherapeutics Inc. (LABT)